The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...

Nemolizumab significantly and safely improved itch and skin lesions for up to 2 years in patients with moderate to severe prurigo nodularis.

Here we demonstrate that AIDS-KS cells express surface interleukin-4 (IL-4) receptors, and that IL-4 toxin (IL-4(38-37)-PE38KDEL) is specifically cytotoxic to these cells. Intratumoral ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

BARCELONA -- Rheumatoid arthritis (RA) patients saw significant reductions in pain with transcranial direct current ...

The presentations are available on Connect’s website under the presentations and publications section.

Enthesitis is a key, but often overlooked, feature of psoriatic arthritis. Learn how this inflammation at tendon and ligament attachment sites can affect diagnosis, symptoms, and treatment.

Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, Department of Pharmaceutics Sciences, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China ...

Sanofi presents positive results from DISCOVER phase 4 study of Dupixent in atopic dermatitis patients with skin of colour at 2025 RAD conference: Paris Tuesday, June 10, 2025, 16 ...